← Back to all trials
Completed
NCT06944704
Evaluation of Efficacy, Safety and Molecular Mechanism of Pentoxifylline Supplementation in Patients With Hepatic and Obstructive Jaundice
Conditions: Hepatobiliary Disorders
Sex: All
Ages: 18 Years – 70 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 45
Sponsor: Tanta University
Location: Faculty of Pharmacy, Tanta University Tanta
Summary
Investigating the efficacy, safety, and molecular mechanism of Pentoxifylline supplementation in improving elevated direct bilirubin level and liver function tests in patients with hepatic and post-hepatic jaundice
Eligibility Criteria
Inclusion Criteria:
* Patients age 18-70 years old.
* Patients diagnosed with jaundice and increased level direct bilirubin ≥ 3 mg/dL.
Exclusion Criteria:
* Pregnancy.
* Nursing mothers.
* Patients with increased indirect bilirubin level.
* Patients who have Gilbert syndrome or Crigler Najjar syndrome.
* History of intolerance and hypersensitivity to Pentoxifylline or to xanthine derivatives such as caffeine, theophylline.
* Recent hemorrhage.
* Patients who have risk factors potentially complicated by hemorrhage.
* Taking anticoagulants or antiplatelet therapy.
Source: ClinicalTrials.gov (NCT06944704). StuddyBuddy aggregates publicly available trial information.
